IPO - KAZIA THERAPEUTICS LTD

Form Type: CORRESP

Filing Date: 2025-02-03

Corporate Action: Ipo

Type: New

Accession Number: 000119312525018914

Filing Summary: Kazia Therapeutics Limited is requesting the acceleration of the effective date for their Registration Statement on Form F-1, with the aim to have it effective by February 5, 2025, at 4:00 p.m. Eastern Time. The request is submitted under Rule 461 of the Securities Act of 1933. The company is aware of its responsibilities under the Act during the acceleration process. For further inquiries, the document provides contact details for Stephanie Richards of Goodwin Procter LLP.

Document Link: View Document

Form Type: F-1

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: New

Accession Number: 000119312525017288

Filing Summary: Kazia Therapeutics Limited, an oncology-focused biotechnology company, registered a total of up to 1,373,333 American Depositary Shares (ADSs) representing 137,333,300 ordinary shares for resale by selling shareholders. Each ADS represents 100 ordinary shares. The offering is linked to warrants from a private placement in January 2025 which are also part of this registration. The sales will be conducted through various public or private channels, with proceeds going entirely to the selling shareholders, while Kazia does not expect to receive any proceeds from the sale of these ADSs. The company will, however, receive funds from any exercise of the warrants. Kazia is classified as a foreign private issuer and is therefore subject to reduced reporting requirements under U.S. securities laws. The ADSs are listed on the Nasdaq Capital Market under the symbol 'KZIA'. The filing includes potential risks associated with investing in these securities and emphasizes the speculative nature of such investments.

Document Link: View Document